InSite Vision names Louis Drapeau interim CEO

InSite Vision (US) has announced that Louis Drapeau, its vice-president and chief financial officer, has been appointed interim CEO. Dr S Kumar Chandrasekaran will step down as CEO, effective immediately. Mr Drapeau will lead the company's day-to-day operations while retaining his CFO responsibilities; the search for a CEO has begun. In addition, Dr Evan Melrose, managing director of PTV Sciences, has been named chairman of the board.

InSite Vision (US) has announced that Louis Drapeau, its vice-president and chief financial officer, has been appointed interim CEO. Dr S Kumar Chandrasekaran will step down as CEO, effective immediately. Mr Drapeau will lead the company's day-to-day operations while retaining his CFO responsibilities; the search for a CEO has begun. In addition, Dr Evan Melrose, managing director of PTV Sciences, has been named chairman of the board.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By 

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By 

Coartem Baby to be rolled out in eight African countries in the autumn.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By 

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

More from Scrip

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.